Estrella Immunopharma(ESLA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ESLA Estrella Immunopharma

盘后交易 10-06 16:10:09 EDT

0.4290

-0.0110

-2.50%

盘后0.4290

+0.00000.00%

16:04 EDT

最高0.4606	最低0.4111	成交量6.86万
今开0.4422	昨收0.4400	日振幅11.25%
总市值1,866万	流通市值1,639万	总股本4,350万
成交额2.98万	换手率0.18%	流通股本3,821万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ESLA","market":"US","secType":"STK","nameCN":"Estrella Immunopharma","latestPrice":0.429,"timestamp":1791316800000,"preClose":0.44,"halted":0,"volume":68647,"hourTrading":{"tag":"盘后","latestPrice":0.429,"preClose":0.429,"latestTime":"16:04 EDT","volume":294,"amount":126.126,"timestamp":1791317043226,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.025000000000000022,"floatShares":38214100,"shares":43497864,"eps":-0.250235,"marketStatus":"盘后交易","change":-0.011,"latestTime":"10-06 16:10:09 EDT","open":0.4422,"high":0.4606,"low":0.4111,"amount":29752,"amplitude":0.1125,"askPrice":0.5101,"askSize":100,"bidPrice":0.3769,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.250235,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791331200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":0.44,"postHourTrading":{"tag":"盘后","latestPrice":0.429,"preClose":0.429,"latestTime":"16:04 EDT","volume":294,"amount":126.126,"timestamp":1791317043226,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":3.264894},"requestUrl":"/m/hq/s/ESLA/","defaultTab":"news","newsList":[{"id":"1131143670","title":"Estrella Immunopharma激活克利夫兰大学医院医学中心，作为B细胞非霍奇金淋巴瘤I/II期Starlight-1试验的第四临床中心","url":"https://stock-news.laohu8.com/highlight/detail?id=1131143670","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131143670?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:02","pubTimestamp":1786449774,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma正式将克利夫兰大学医院医学中心（University Hospitals Cleveland Medical Center）纳为其I/II期Starlight-1临床试验的第四临床中心。该试验专注于B细胞非霍奇金淋巴瘤的治疗。这一扩展标志着公司在推进该疗法临床研究道路上迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ESLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126090462","title":"Estrella Immunopharma启动俄勒冈健康与科学大学作为B细胞非霍奇金淋巴瘤Starlight-1 I/II期临床试验第三中心","url":"https://stock-news.laohu8.com/highlight/detail?id=1126090462","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1126090462?lang=zh_cn&edition=full","pubTime":"2026-08-03 20:01","pubTimestamp":1785758471,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma近日宣布，已正式激活俄勒冈健康与科学大学（OHSU）作为其Starlight-1 I/II期临床试验的第三家临床中心。该试验聚焦于治疗B细胞非霍奇金淋巴瘤，旨在评估新型疗法的安全性与有效性。这一里程碑标志着公司扩展临床网络、加速试验进程的最新举措。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112591689","title":"Estrella Immunopharma宣布Starlight-1试验剂量扩展阶段首例患者给药，并报告晚期B细胞非霍奇金淋巴瘤持久缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=1112591689","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112591689?lang=zh_cn&edition=full","pubTime":"2026-07-24 20:02","pubTimestamp":1784894545,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma今日宣布，其Starlight-1试验已进入剂量扩展阶段，并成功完成了首例患者给药。与此同时，该公司还公布了在晚期B细胞非霍奇金淋巴瘤患者中观察到的持久缓解率数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518720833","title":"Estrella Immunopharma, Inc.盘中异动 大幅跳水8.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518720833","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518720833?lang=zh_cn&edition=full","pubTime":"2025-03-11 00:22","pubTimestamp":1741623768,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日00时22分，Estrella Immunopharma, Inc.股票出现波动，股价快速下跌8.84%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。其相关个股中，Mineralys Therapeutics, Inc.、Checkpoint Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Aeon Biopharma, Inc.、Scisparc Ltd.较为活跃，换手率分别为3707.85%、3218.00%、951.39%，振幅较大的相关个股有Protagenic Therapeutics Inc C/Wts 29/04/2026 、Aeon Biopharma, Inc.、Scisparc Ltd.，振幅分别为88.14%、78.32%、49.87%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311002248964058fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311002248964058fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ESLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517298859","title":"Estrella Immunopharma, Inc.盘中异动 股价大涨5.88%报1.08美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517298859","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517298859?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:36","pubTimestamp":1741206965,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时36分，Estrella Immunopharma, Inc.股票出现波动，股价大幅上涨5.88%。截至发稿，该股报1.08美元/股，成交量1.7955万股，换手率0.05%，振幅7.84%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体涨幅为1.92%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306043605a2612c13&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306043605a2612c13&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ESLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516637380","title":"Estrella Immunopharma, Inc.盘中异动 早盘快速下跌5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637380","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516637380?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:49","pubTimestamp":1741013384,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时49分，Estrella Immunopharma, Inc.股票出现波动，股价快速跳水5.83%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032249449637b1a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032249449637b1a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ESLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514376386","title":"Estrella Immunopharma, Inc.盘中异动 早盘股价大涨5.19%报1.010美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514376386","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514376386?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:16","pubTimestamp":1740755776,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日23时16分，Estrella Immunopharma, Inc.股票出现波动，股价大幅拉升5.19%。截至发稿，该股报1.010美元/股，成交量1.0893万股，换手率0.03%，振幅1.04%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.25%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022823161698968437&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022823161698968437&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ESLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514387460","title":"Estrella Immunopharma, Inc.盘中异动 早盘股价大跌5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514387460","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514387460?lang=zh_cn&edition=full","pubTime":"2025-02-28 00:41","pubTimestamp":1740674497,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日00时41分，Estrella Immunopharma, Inc.股票出现异动，股价大幅跳水5.45%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228004137a25699d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228004137a25699d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ESLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514517618","title":"Estrella Immunopharma, Inc.盘中异动 股价大跌5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514517618","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514517618?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:48","pubTimestamp":1740581335,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时48分，Estrella Immunopharma, Inc.股票出现异动，股价大幅下跌5.17%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.28%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226224856abddf181&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226224856abddf181&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ESLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514182740","title":"Estrella Immunopharma, Inc.盘中异动 早盘股价大跌6.78%报1.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514182740","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514182740?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:45","pubTimestamp":1740494729,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时45分，Estrella Immunopharma, Inc.股票出现异动，股价急速跳水6.78%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。其相关个股中，Organovo Holdings, Inc.、Gt Biopharma, Inc.、Adial Pharmaceuticals, Inc涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为875.90%、636.03%、533.95%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Gt Biopharma, Inc.，振幅分别为100.27%、46.65%、33.50%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225224530abdc81c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225224530abdc81c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ESLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513751722","title":"Estrella Immunopharma, Inc.盘中异动 大幅跳水18.18%报1.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513751722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513751722?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:31","pubTimestamp":1740407517,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时31分，Estrella Immunopharma, Inc.股票出现异动，股价急速跳水18.18%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223157a2521459&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223157a2521459&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ESLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513909762","title":"D. Boral Capital：维持Estrella Immunopharma(ESLA.US)评级，由买入调整至买入评级, 目标价由16.00美元调整至16.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513909762","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513909762?lang=zh_cn&edition=full","pubTime":"2025-02-22 00:51","pubTimestamp":1740156681,"startTime":"0","endTime":"0","summary":"D. Boral Capital：维持Estrella Immunopharma(ESLA.US)评级，由买入调整至买入评级, 目标价由16.00美元调整至16.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22005148320974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ESLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513296581","title":"Estrella Immunopharma, Inc.股价飙升13.42% 市值涨820.54万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513296581","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513296581?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:31","pubTimestamp":1740148262,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时31分，Estrella Immunopharma, Inc.股票出现异动，股价大幅上涨13.42%。截至发稿，该股报1.69美元/股，成交量10.6477万股，换手率0.29%，振幅0.00%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223102a24eaff6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221223102a24eaff6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ESLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512166470","title":"Estrella Immunopharma, Inc.盘中异动 快速上涨12.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512166470","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512166470?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:32","pubTimestamp":1739889130,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时32分，Estrella Immunopharma, Inc.股票出现波动，股价快速拉升12.15%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.11%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Glycomimetics, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为276.23%、91.16%、60.68%，振幅较大的相关个股有Allogene Therapeutics, Inc.、Cns Pharmaceuticals, Inc.、Allakos Inc.，振幅分别为9.56%、8.57%、8.35%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223210a24aacc0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223210a24aacc0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ESLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512519901","title":"Estrella Immunopharma(ESLA.US)获D. Boral Capital首次覆盖，给予买入评级, 目标价16.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2512519901","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512519901?lang=zh_cn&edition=full","pubTime":"2025-02-18 20:24","pubTimestamp":1739881496,"startTime":"0","endTime":"0","summary":"Estrella Immunopharma(ESLA.US)获D. Boral Capital首次覆盖，给予买入评级, 目标价16.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/18202448237104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ESLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511716697","title":"Estrella Immunopharma, Inc.股价拉升12.38% 市值涨188.69万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511716697","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511716697?lang=zh_cn&edition=full","pubTime":"2025-02-15 00:41","pubTimestamp":1739551271,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日00时41分，Estrella Immunopharma, Inc.股票出现异动，股价快速拉升12.38%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021500411196233933&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021500411196233933&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ESLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511269525","title":"Estrella Immunopharma, Inc.盘中异动 快速上涨5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511269525","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511269525?lang=zh_cn&edition=full","pubTime":"2025-02-13 22:43","pubTimestamp":1739457781,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时43分，Estrella Immunopharma, Inc.股票出现波动，股价急速拉升5.31%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.17%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213224301a244adf5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213224301a244adf5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ESLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510526303","title":"Estrella Immunopharma, Inc.盘中异动 临近收盘急速拉升6.54%报1.14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510526303","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510526303?lang=zh_cn&edition=full","pubTime":"2025-02-12 04:50","pubTimestamp":1739307015,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日04时50分，Estrella Immunopharma, Inc.股票出现异动，股价大幅拉升6.54%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为2.02%。其相关个股中，Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为3245.87%、1559.43%、521.43%，振幅较大的相关个股有Omega Therapeutics, Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.，振幅分别为143.33%、72.23%、64.94%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120450159881f924&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502120450159881f924&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ESLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510613238","title":"Estrella Immunopharma, Inc.盘中异动 早盘股价大跌5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510613238","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510613238?lang=zh_cn&edition=full","pubTime":"2025-02-10 23:44","pubTimestamp":1739202242,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日23时44分，Estrella Immunopharma, Inc.股票出现波动，股价快速跳水5.36%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.08%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210234402abc9b513&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210234402abc9b513&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ESLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509248270","title":"Estrella Immunopharma, Inc.盘中异动 大幅拉升8.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509248270","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509248270?lang=zh_cn&edition=full","pubTime":"2025-02-06 22:31","pubTimestamp":1738852265,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日22时31分，Estrella Immunopharma, Inc.股票出现波动，股价快速上涨8.68%。Estrella Immunopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.12%。Estrella Immunopharma, Inc.公司简介：Estrella Immunopharma Inc 是一家临床阶段的生物制药公司，开发针对 CD19 和 CD22 的 ARTEMIS T 细胞疗法，用以解决血癌和实体瘤患者的治疗挑战。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223105961a190e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206223105961a190e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ESLA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.estrellabio.com","stockEarnings":[{"period":"1week","weight":0.0199},{"period":"1month","weight":-0.3192},{"period":"3month","weight":-0.5165},{"period":"6month","weight":-0.7708},{"period":"1year","weight":-0.6641},{"period":"ytd","weight":-0.7179}],"compareEarnings":[{"period":"1week","weight":0.012},{"period":"1month","weight":0.006},{"period":"3month","weight":0.0363},{"period":"6month","weight":0.1462},{"period":"1year","weight":0.1578},{"period":"ytd","weight":0.1362}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Estrella Immunopharma, Inc.于2022年3月30日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司，利用其专有的ARTEMIS技术开发针对血液癌症和实体瘤的T细胞疗法。其主要候选药物EB103靶向CD19用于治疗B细胞恶性肿瘤，同时也在开发双靶向候选药物EB104。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.071617},{"month":2,"riseRate":0.6,"avgChangeRate":-0.002484},{"month":3,"riseRate":0.4,"avgChangeRate":-0.005084},{"month":4,"riseRate":0.8,"avgChangeRate":0.114262},{"month":5,"riseRate":0.2,"avgChangeRate":-0.099189},{"month":6,"riseRate":0.4,"avgChangeRate":0.004839},{"month":7,"riseRate":0.4,"avgChangeRate":-0.003814},{"month":8,"riseRate":0.4,"avgChangeRate":-0.04031},{"month":9,"riseRate":0.6,"avgChangeRate":-0.011991},{"month":10,"riseRate":0.5,"avgChangeRate":-0.014332},{"month":11,"riseRate":0.8,"avgChangeRate":0.071826},{"month":12,"riseRate":0.2,"avgChangeRate":-0.109506}],"exchange":"NASDAQ","name":"Estrella Immunopharma","nameEN":"Estrella Immunopharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Estrella Immunopharma(ESLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Estrella Immunopharma(ESLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Estrella Immunopharma,ESLA,Estrella Immunopharma股票,Estrella Immunopharma股票老虎,Estrella Immunopharma股票老虎国际,Estrella Immunopharma行情,Estrella Immunopharma股票行情,Estrella Immunopharma股价,Estrella Immunopharma股市,Estrella Immunopharma股票价格,Estrella Immunopharma股票交易,Estrella Immunopharma股票购买,Estrella Immunopharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Estrella Immunopharma(ESLA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Estrella Immunopharma(ESLA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}